ID

17833

Description

Safety of Diamyd® in Patients With LADA (Latent Autoimmune Diabetes in Adult); ODM derived from: https://clinicaltrials.gov/show/NCT00456027

Lien

https://clinicaltrials.gov/show/NCT00456027

Mots-clés

Versions (1)
  1. 04/10/2016 04/10/2016 -
Téléchargé le

4 octobre 2016

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Latent Autoimmune Diabetes in Adult (LADA) NCT00456027

Anglais

Eligibility Latent Autoimmune Diabetes in Adult (LADA) NCT00456027

1 Formulaires  
Criteria
Description

Criteria

male and female patients between 30-70 years of age diagnosed with type 2 diabetes within 5 years
Description

Age | Diabetes Mellitus, Non-Insulin-Dependent

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0011860
presence of gad65 antibodies
Description

Serum Gad65 Auto Antibodies Test Positive

Type de données

boolean

Alias
UMLS CUI [1,1]
C1255118
UMLS CUI [1,2]
C1514241
detectable c-peptide level
Description

C-peptide level Detectable

Type de données

boolean

Alias
UMLS CUI [1,1]
C0202100
UMLS CUI [1,2]
C3830527
patients requiring treatment with diet and/or oral hypoglycaemic agents (oha)
Description

Diet therapy Patient need for | Oral hypoglycemic Patient need for

Type de données

boolean

Alias
UMLS CUI [1,1]
C0012159
UMLS CUI [1,2]
C0686904
UMLS CUI [2,1]
C0359086
UMLS CUI [2,2]
C0686904
written informed consent
Description

Informed Consent

Type de données

boolean

Alias
UMLS CUI [1]
C0021430
key exclusion criteria:
Description

Exclusion Criteria Main

Type de données

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C1542147
treatment with insulin
Description

Insulin regime

Type de données

boolean

Alias
UMLS CUI [1]
C0557978
intolerance to oha
Description

intolerance to Oral hypoglycemic

Type de données

boolean

Alias
UMLS CUI [1,1]
C1744706
UMLS CUI [1,2]
C0359086
secondary diabetes mellitus
Description

Secondary diabetes mellitus

Type de données

boolean

Alias
UMLS CUI [1]
C0271640
history of certain diseases or conditions (e.g. anaemia, epilepsy, head trauma, neurological disease, alcohol or drug abuse, hiv, hepatitis)
Description

Disease Any | medical condition Any | Anemia | Epilepsy | Craniocerebral Trauma | nervous system disorder | Substance Use Disorders | HIV | Hepatitis

Type de données

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C1552551
UMLS CUI [2,1]
C3843040
UMLS CUI [2,2]
C1552551
UMLS CUI [3]
C0002871
UMLS CUI [4]
C0014544
UMLS CUI [5]
C0018674
UMLS CUI [6]
C0027765
UMLS CUI [7]
C0038586
UMLS CUI [8]
C0019682
UMLS CUI [9]
C0019158
treatment with any vaccine within one month prior to first diamyd® dose or planned treatment with vaccine up to 2 months after the second diamyd® dose
Description

Vaccine Any | Glutamate decarboxylase 65 Dose Ordinal number

Type de données

boolean

Alias
UMLS CUI [1,1]
C0042210
UMLS CUI [1,2]
C1552551
UMLS CUI [2,1]
C1291583
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C0439080
participation in other clinical trials with a new chemical entity within the previous 3 months
Description

Study Subject Participation Status | Chemicals Investigational

Type de données

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2,1]
C0220806
UMLS CUI [2,2]
C1517586
pregnancy (or planned pregnancy within one year after 2nd administration)
Description

Pregnancy | Pregnancy, Planned

Type de données

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0032992
presence of associated serious disease or condition which in the opinion of the investigator makes the patient non-eligible for the study
Description

Comorbidity Serious Study Subject Participation Status Ineligible | medical condition Serious Study Subject Participation Status Ineligible

Type de données

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0205404
UMLS CUI [1,3]
C2348568
UMLS CUI [1,4]
C1512714
UMLS CUI [2,1]
C3843040
UMLS CUI [2,2]
C0205404
UMLS CUI [2,3]
C2348568
UMLS CUI [2,4]
C1512714
significant illness other than diabetes within 2 weeks prior to first dosing
Description

Illness Significant | Diabetes Mellitus

Type de données

boolean

Alias
UMLS CUI [1,1]
C0221423
UMLS CUI [1,2]
C0750502
UMLS CUI [2]
C0011849
unwillingness to comply with the provisions of the protocol
Description

Protocol Compliance Unwilling

Type de données

boolean

Alias
UMLS CUI [1,1]
C0525058
UMLS CUI [1,2]
C0558080
clinically significant history of acute reaction to drugs in the past
Description

Acute allergic reaction Clinical Significant Pharmaceutical Preparations

Type de données

boolean

Alias
UMLS CUI [1,1]
C0413234
UMLS CUI [1,2]
C2826293
UMLS CUI [1,3]
C0013227
treatment with immunosuppressants
Description

Immunosuppressive Agents

Type de données

boolean

Alias
UMLS CUI [1]
C0021081
Retour au début de la page

Similar models

Eligibility Latent Autoimmune Diabetes in Adult (LADA) NCT00456027

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Age | Diabetes Mellitus, Non-Insulin-Dependent
Item
male and female patients between 30-70 years of age diagnosed with type 2 diabetes within 5 years
boolean
C0001779 (UMLS CUI [1])
C0011860 (UMLS CUI [2])
Serum Gad65 Auto Antibodies Test Positive
Item
presence of gad65 antibodies
boolean
C1255118 (UMLS CUI [1,1])
C1514241 (UMLS CUI [1,2])
C-peptide level Detectable
Item
detectable c-peptide level
boolean
C0202100 (UMLS CUI [1,1])
C3830527 (UMLS CUI [1,2])
Diet therapy Patient need for | Oral hypoglycemic Patient need for
Item
patients requiring treatment with diet and/or oral hypoglycaemic agents (oha)
boolean
C0012159 (UMLS CUI [1,1])
C0686904 (UMLS CUI [1,2])
C0359086 (UMLS CUI [2,1])
C0686904 (UMLS CUI [2,2])
Informed Consent
Item
written informed consent
boolean
C0021430 (UMLS CUI [1])
Exclusion Criteria Main
Item
key exclusion criteria:
boolean
C0680251 (UMLS CUI [1,1])
C1542147 (UMLS CUI [1,2])
Insulin regime
Item
treatment with insulin
boolean
C0557978 (UMLS CUI [1])
intolerance to Oral hypoglycemic
Item
intolerance to oha
boolean
C1744706 (UMLS CUI [1,1])
C0359086 (UMLS CUI [1,2])
Secondary diabetes mellitus
Item
secondary diabetes mellitus
boolean
C0271640 (UMLS CUI [1])
Disease Any | medical condition Any | Anemia | Epilepsy | Craniocerebral Trauma | nervous system disorder | Substance Use Disorders | HIV | Hepatitis
Item
history of certain diseases or conditions (e.g. anaemia, epilepsy, head trauma, neurological disease, alcohol or drug abuse, hiv, hepatitis)
boolean
C0012634 (UMLS CUI [1,1])
C1552551 (UMLS CUI [1,2])
C3843040 (UMLS CUI [2,1])
C1552551 (UMLS CUI [2,2])
C0002871 (UMLS CUI [3])
C0014544 (UMLS CUI [4])
C0018674 (UMLS CUI [5])
C0027765 (UMLS CUI [6])
C0038586 (UMLS CUI [7])
C0019682 (UMLS CUI [8])
C0019158 (UMLS CUI [9])
Vaccine Any | Glutamate decarboxylase 65 Dose Ordinal number
Item
treatment with any vaccine within one month prior to first diamyd® dose or planned treatment with vaccine up to 2 months after the second diamyd® dose
boolean
C0042210 (UMLS CUI [1,1])
C1552551 (UMLS CUI [1,2])
C1291583 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0439080 (UMLS CUI [2,3])
Study Subject Participation Status | Chemicals Investigational
Item
participation in other clinical trials with a new chemical entity within the previous 3 months
boolean
C2348568 (UMLS CUI [1])
C0220806 (UMLS CUI [2,1])
C1517586 (UMLS CUI [2,2])
Pregnancy | Pregnancy, Planned
Item
pregnancy (or planned pregnancy within one year after 2nd administration)
boolean
C0032961 (UMLS CUI [1])
C0032992 (UMLS CUI [2])
Comorbidity Serious Study Subject Participation Status Ineligible | medical condition Serious Study Subject Participation Status Ineligible
Item
presence of associated serious disease or condition which in the opinion of the investigator makes the patient non-eligible for the study
boolean
C0009488 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C2348568 (UMLS CUI [1,3])
C1512714 (UMLS CUI [1,4])
C3843040 (UMLS CUI [2,1])
C0205404 (UMLS CUI [2,2])
C2348568 (UMLS CUI [2,3])
C1512714 (UMLS CUI [2,4])
Illness Significant | Diabetes Mellitus
Item
significant illness other than diabetes within 2 weeks prior to first dosing
boolean
C0221423 (UMLS CUI [1,1])
C0750502 (UMLS CUI [1,2])
C0011849 (UMLS CUI [2])
Protocol Compliance Unwilling
Item
unwillingness to comply with the provisions of the protocol
boolean
C0525058 (UMLS CUI [1,1])
C0558080 (UMLS CUI [1,2])
Acute allergic reaction Clinical Significant Pharmaceutical Preparations
Item
clinically significant history of acute reaction to drugs in the past
boolean
C0413234 (UMLS CUI [1,1])
C2826293 (UMLS CUI [1,2])
C0013227 (UMLS CUI [1,3])
Immunosuppressive Agents
Item
treatment with immunosuppressants
boolean
C0021081 (UMLS CUI [1])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial